Antibody Drug Conjugate-Europe Market Status and Trend Report 2013-2023
Report Summary
Antibody Drug Conjugate-Europe Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Antibody Drug Conjugate industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole Europe and Regional Market Size of Antibody Drug Conjugate 2013-2017, and development forecast 2018-2023
Main market players of Antibody Drug Conjugate in Europe, with company and product introduction, position in the Antibody Drug Conjugate market
Market status and development trend of Antibody Drug Conjugate by types and applications
Cost and profit status of Antibody Drug Conjugate, and marketing status
Market growth drivers and challenges
The report segments the Europe Antibody Drug Conjugate market as:
Europe Antibody Drug Conjugate Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
Germany
United Kingdom
France
Italy
Spain
Benelux
Russia
Europe Antibody Drug Conjugate Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Adcetris
Kadcyl
Other
Europe Antibody Drug Conjugate Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Hospital
Pharmaceutical Company
Research Institutions
Europe Antibody Drug Conjugate Market: Players Segment Analysis (Company and Product introduction, Antibody Drug Conjugate Sales Volume, Revenue, Price and Gross Margin):
Seattle Genetics/Takeda
Roche
ImmunoGen
Immunomedics
Pfizer
Celldex Therapeutics
Millennium Pharmaceuticals
Bayer HealthCare
Mersana Therapeutics
Heidelberg Pharma
Oxford BioTherapeutics
Takeda Pharmaceutical Company Limited
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
Antibody Drug Conjugate-Europe Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Antibody Drug Conjugate industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole Europe and Regional Market Size of Antibody Drug Conjugate 2013-2017, and development forecast 2018-2023
Main market players of Antibody Drug Conjugate in Europe, with company and product introduction, position in the Antibody Drug Conjugate market
Market status and development trend of Antibody Drug Conjugate by types and applications
Cost and profit status of Antibody Drug Conjugate, and marketing status
Market growth drivers and challenges
The report segments the Europe Antibody Drug Conjugate market as:
Europe Antibody Drug Conjugate Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
Germany
United Kingdom
France
Italy
Spain
Benelux
Russia
Europe Antibody Drug Conjugate Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Adcetris
Kadcyl
Other
Europe Antibody Drug Conjugate Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Hospital
Pharmaceutical Company
Research Institutions
Europe Antibody Drug Conjugate Market: Players Segment Analysis (Company and Product introduction, Antibody Drug Conjugate Sales Volume, Revenue, Price and Gross Margin):
Seattle Genetics/Takeda
Roche
ImmunoGen
Immunomedics
Pfizer
Celldex Therapeutics
Millennium Pharmaceuticals
Bayer HealthCare
Mersana Therapeutics
Heidelberg Pharma
Oxford BioTherapeutics
Takeda Pharmaceutical Company Limited
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF ANTIBODY DRUG CONJUGATE
1.1 Definition of Antibody Drug Conjugate in This Report
1.2 Commercial Types of Antibody Drug Conjugate
1.2.1 Adcetris
1.2.2 Kadcyl
1.2.3 Other
1.3 Downstream Application of Antibody Drug Conjugate
1.3.1 Hospital
1.3.2 Pharmaceutical Company
1.3.3 Research Institutions
1.4 Development History of Antibody Drug Conjugate
1.5 Market Status and Trend of Antibody Drug Conjugate 2013-2023
1.5.1 Europe Antibody Drug Conjugate Market Status and Trend 2013-2023
1.5.2 Regional Antibody Drug Conjugate Market Status and Trend 2013-2023
CHAPTER 2 EUROPE MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of Antibody Drug Conjugate in Europe 2013-2017
2.2 Consumption Market of Antibody Drug Conjugate in Europe by Regions
2.2.1 Consumption Volume of Antibody Drug Conjugate in Europe by Regions
2.2.2 Revenue of Antibody Drug Conjugate in Europe by Regions
2.3 Market Analysis of Antibody Drug Conjugate in Europe by Regions
2.3.1 Market Analysis of Antibody Drug Conjugate in Germany 2013-2017
2.3.2 Market Analysis of Antibody Drug Conjugate in United Kingdom 2013-2017
2.3.3 Market Analysis of Antibody Drug Conjugate in France 2013-2017
2.3.4 Market Analysis of Antibody Drug Conjugate in Italy 2013-2017
2.3.5 Market Analysis of Antibody Drug Conjugate in Spain 2013-2017
2.3.6 Market Analysis of Antibody Drug Conjugate in Benelux 2013-2017
2.3.7 Market Analysis of Antibody Drug Conjugate in Russia 2013-2017
2.4 Market Development Forecast of Antibody Drug Conjugate in Europe 2018-2023
2.4.1 Market Development Forecast of Antibody Drug Conjugate in Europe 2018-2023
2.4.2 Market Development Forecast of Antibody Drug Conjugate by Regions 2018-2023
CHAPTER 3 EUROPE MARKET STATUS AND FORECAST BY TYPES
3.1 Whole Europe Market Status by Types
3.1.1 Consumption Volume of Antibody Drug Conjugate in Europe by Types
3.1.2 Revenue of Antibody Drug Conjugate in Europe by Types
3.2 Europe Market Status by Types in Major Countries
3.2.1 Market Status by Types in Germany
3.2.2 Market Status by Types in United Kingdom
3.2.3 Market Status by Types in France
3.2.4 Market Status by Types in Italy
3.2.5 Market Status by Types in Spain
3.2.6 Market Status by Types in Benelux
3.2.7 Market Status by Types in Russia
3.3 Market Forecast of Antibody Drug Conjugate in Europe by Types
CHAPTER 4 EUROPE MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Antibody Drug Conjugate in Europe by Downstream Industry
4.2 Demand Volume of Antibody Drug Conjugate by Downstream Industry in Major Countries
4.2.1 Demand Volume of Antibody Drug Conjugate by Downstream Industry in Germany
4.2.2 Demand Volume of Antibody Drug Conjugate by Downstream Industry in United Kingdom
4.2.3 Demand Volume of Antibody Drug Conjugate by Downstream Industry in France
4.2.4 Demand Volume of Antibody Drug Conjugate by Downstream Industry in Italy
4.2.5 Demand Volume of Antibody Drug Conjugate by Downstream Industry in Spain
4.2.6 Demand Volume of Antibody Drug Conjugate by Downstream Industry in Benelux
4.2.7 Demand Volume of Antibody Drug Conjugate by Downstream Industry in Russia
4.3 Market Forecast of Antibody Drug Conjugate in Europe by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF ANTIBODY DRUG CONJUGATE
5.1 Europe Economy Situation and Trend Overview
5.2 Antibody Drug Conjugate Downstream Industry Situation and Trend Overview
CHAPTER 6 ANTIBODY DRUG CONJUGATE MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EUROPE
6.1 Sales Volume of Antibody Drug Conjugate in Europe by Major Players
6.2 Revenue of Antibody Drug Conjugate in Europe by Major Players
6.3 Basic Information of Antibody Drug Conjugate by Major Players
6.3.1 Headquarters Location and Established Time of Antibody Drug Conjugate Major Players
6.3.2 Employees and Revenue Level of Antibody Drug Conjugate Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 ANTIBODY DRUG CONJUGATE MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Seattle Genetics/Takeda
7.1.1 Company profile
7.1.2 Representative Antibody Drug Conjugate Product
7.1.3 Antibody Drug Conjugate Sales, Revenue, Price and Gross Margin of Seattle Genetics/Takeda
7.2 Roche
7.2.1 Company profile
7.2.2 Representative Antibody Drug Conjugate Product
7.2.3 Antibody Drug Conjugate Sales, Revenue, Price and Gross Margin of Roche
7.3 ImmunoGen
7.3.1 Company profile
7.3.2 Representative Antibody Drug Conjugate Product
7.3.3 Antibody Drug Conjugate Sales, Revenue, Price and Gross Margin of ImmunoGen
7.4 Immunomedics
7.4.1 Company profile
7.4.2 Representative Antibody Drug Conjugate Product
7.4.3 Antibody Drug Conjugate Sales, Revenue, Price and Gross Margin of Immunomedics
7.5 Pfizer
7.5.1 Company profile
7.5.2 Representative Antibody Drug Conjugate Product
7.5.3 Antibody Drug Conjugate Sales, Revenue, Price and Gross Margin of Pfizer
7.6 Celldex Therapeutics
7.6.1 Company profile
7.6.2 Representative Antibody Drug Conjugate Product
7.6.3 Antibody Drug Conjugate Sales, Revenue, Price and Gross Margin of Celldex Therapeutics
7.7 Millennium Pharmaceuticals
7.7.1 Company profile
7.7.2 Representative Antibody Drug Conjugate Product
7.7.3 Antibody Drug Conjugate Sales, Revenue, Price and Gross Margin of Millennium Pharmaceuticals
7.8 Bayer HealthCare
7.8.1 Company profile
7.8.2 Representative Antibody Drug Conjugate Product
7.8.3 Antibody Drug Conjugate Sales, Revenue, Price and Gross Margin of Bayer HealthCare
7.9 Mersana Therapeutics
7.9.1 Company profile
7.9.2 Representative Antibody Drug Conjugate Product
7.9.3 Antibody Drug Conjugate Sales, Revenue, Price and Gross Margin of Mersana Therapeutics
7.10 Heidelberg Pharma
7.10.1 Company profile
7.10.2 Representative Antibody Drug Conjugate Product
7.10.3 Antibody Drug Conjugate Sales, Revenue, Price and Gross Margin of Heidelberg Pharma
7.11 Oxford BioTherapeutics
7.11.1 Company profile
7.11.2 Representative Antibody Drug Conjugate Product
7.11.3 Antibody Drug Conjugate Sales, Revenue, Price and Gross Margin of Oxford BioTherapeutics
7.12 Takeda Pharmaceutical Company Limited
7.12.1 Company profile
7.12.2 Representative Antibody Drug Conjugate Product
7.12.3 Antibody Drug Conjugate Sales, Revenue, Price and Gross Margin of Takeda Pharmaceutical Company Limited
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF ANTIBODY DRUG CONJUGATE
8.1 Industry Chain of Antibody Drug Conjugate
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF ANTIBODY DRUG CONJUGATE
9.1 Cost Structure Analysis of Antibody Drug Conjugate
9.2 Raw Materials Cost Analysis of Antibody Drug Conjugate
9.3 Labor Cost Analysis of Antibody Drug Conjugate
9.4 Manufacturing Expenses Analysis of Antibody Drug Conjugate
CHAPTER 10 MARKETING STATUS ANALYSIS OF ANTIBODY DRUG CONJUGATE
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
1.1 Definition of Antibody Drug Conjugate in This Report
1.2 Commercial Types of Antibody Drug Conjugate
1.2.1 Adcetris
1.2.2 Kadcyl
1.2.3 Other
1.3 Downstream Application of Antibody Drug Conjugate
1.3.1 Hospital
1.3.2 Pharmaceutical Company
1.3.3 Research Institutions
1.4 Development History of Antibody Drug Conjugate
1.5 Market Status and Trend of Antibody Drug Conjugate 2013-2023
1.5.1 Europe Antibody Drug Conjugate Market Status and Trend 2013-2023
1.5.2 Regional Antibody Drug Conjugate Market Status and Trend 2013-2023
CHAPTER 2 EUROPE MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of Antibody Drug Conjugate in Europe 2013-2017
2.2 Consumption Market of Antibody Drug Conjugate in Europe by Regions
2.2.1 Consumption Volume of Antibody Drug Conjugate in Europe by Regions
2.2.2 Revenue of Antibody Drug Conjugate in Europe by Regions
2.3 Market Analysis of Antibody Drug Conjugate in Europe by Regions
2.3.1 Market Analysis of Antibody Drug Conjugate in Germany 2013-2017
2.3.2 Market Analysis of Antibody Drug Conjugate in United Kingdom 2013-2017
2.3.3 Market Analysis of Antibody Drug Conjugate in France 2013-2017
2.3.4 Market Analysis of Antibody Drug Conjugate in Italy 2013-2017
2.3.5 Market Analysis of Antibody Drug Conjugate in Spain 2013-2017
2.3.6 Market Analysis of Antibody Drug Conjugate in Benelux 2013-2017
2.3.7 Market Analysis of Antibody Drug Conjugate in Russia 2013-2017
2.4 Market Development Forecast of Antibody Drug Conjugate in Europe 2018-2023
2.4.1 Market Development Forecast of Antibody Drug Conjugate in Europe 2018-2023
2.4.2 Market Development Forecast of Antibody Drug Conjugate by Regions 2018-2023
CHAPTER 3 EUROPE MARKET STATUS AND FORECAST BY TYPES
3.1 Whole Europe Market Status by Types
3.1.1 Consumption Volume of Antibody Drug Conjugate in Europe by Types
3.1.2 Revenue of Antibody Drug Conjugate in Europe by Types
3.2 Europe Market Status by Types in Major Countries
3.2.1 Market Status by Types in Germany
3.2.2 Market Status by Types in United Kingdom
3.2.3 Market Status by Types in France
3.2.4 Market Status by Types in Italy
3.2.5 Market Status by Types in Spain
3.2.6 Market Status by Types in Benelux
3.2.7 Market Status by Types in Russia
3.3 Market Forecast of Antibody Drug Conjugate in Europe by Types
CHAPTER 4 EUROPE MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Antibody Drug Conjugate in Europe by Downstream Industry
4.2 Demand Volume of Antibody Drug Conjugate by Downstream Industry in Major Countries
4.2.1 Demand Volume of Antibody Drug Conjugate by Downstream Industry in Germany
4.2.2 Demand Volume of Antibody Drug Conjugate by Downstream Industry in United Kingdom
4.2.3 Demand Volume of Antibody Drug Conjugate by Downstream Industry in France
4.2.4 Demand Volume of Antibody Drug Conjugate by Downstream Industry in Italy
4.2.5 Demand Volume of Antibody Drug Conjugate by Downstream Industry in Spain
4.2.6 Demand Volume of Antibody Drug Conjugate by Downstream Industry in Benelux
4.2.7 Demand Volume of Antibody Drug Conjugate by Downstream Industry in Russia
4.3 Market Forecast of Antibody Drug Conjugate in Europe by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF ANTIBODY DRUG CONJUGATE
5.1 Europe Economy Situation and Trend Overview
5.2 Antibody Drug Conjugate Downstream Industry Situation and Trend Overview
CHAPTER 6 ANTIBODY DRUG CONJUGATE MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EUROPE
6.1 Sales Volume of Antibody Drug Conjugate in Europe by Major Players
6.2 Revenue of Antibody Drug Conjugate in Europe by Major Players
6.3 Basic Information of Antibody Drug Conjugate by Major Players
6.3.1 Headquarters Location and Established Time of Antibody Drug Conjugate Major Players
6.3.2 Employees and Revenue Level of Antibody Drug Conjugate Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 ANTIBODY DRUG CONJUGATE MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Seattle Genetics/Takeda
7.1.1 Company profile
7.1.2 Representative Antibody Drug Conjugate Product
7.1.3 Antibody Drug Conjugate Sales, Revenue, Price and Gross Margin of Seattle Genetics/Takeda
7.2 Roche
7.2.1 Company profile
7.2.2 Representative Antibody Drug Conjugate Product
7.2.3 Antibody Drug Conjugate Sales, Revenue, Price and Gross Margin of Roche
7.3 ImmunoGen
7.3.1 Company profile
7.3.2 Representative Antibody Drug Conjugate Product
7.3.3 Antibody Drug Conjugate Sales, Revenue, Price and Gross Margin of ImmunoGen
7.4 Immunomedics
7.4.1 Company profile
7.4.2 Representative Antibody Drug Conjugate Product
7.4.3 Antibody Drug Conjugate Sales, Revenue, Price and Gross Margin of Immunomedics
7.5 Pfizer
7.5.1 Company profile
7.5.2 Representative Antibody Drug Conjugate Product
7.5.3 Antibody Drug Conjugate Sales, Revenue, Price and Gross Margin of Pfizer
7.6 Celldex Therapeutics
7.6.1 Company profile
7.6.2 Representative Antibody Drug Conjugate Product
7.6.3 Antibody Drug Conjugate Sales, Revenue, Price and Gross Margin of Celldex Therapeutics
7.7 Millennium Pharmaceuticals
7.7.1 Company profile
7.7.2 Representative Antibody Drug Conjugate Product
7.7.3 Antibody Drug Conjugate Sales, Revenue, Price and Gross Margin of Millennium Pharmaceuticals
7.8 Bayer HealthCare
7.8.1 Company profile
7.8.2 Representative Antibody Drug Conjugate Product
7.8.3 Antibody Drug Conjugate Sales, Revenue, Price and Gross Margin of Bayer HealthCare
7.9 Mersana Therapeutics
7.9.1 Company profile
7.9.2 Representative Antibody Drug Conjugate Product
7.9.3 Antibody Drug Conjugate Sales, Revenue, Price and Gross Margin of Mersana Therapeutics
7.10 Heidelberg Pharma
7.10.1 Company profile
7.10.2 Representative Antibody Drug Conjugate Product
7.10.3 Antibody Drug Conjugate Sales, Revenue, Price and Gross Margin of Heidelberg Pharma
7.11 Oxford BioTherapeutics
7.11.1 Company profile
7.11.2 Representative Antibody Drug Conjugate Product
7.11.3 Antibody Drug Conjugate Sales, Revenue, Price and Gross Margin of Oxford BioTherapeutics
7.12 Takeda Pharmaceutical Company Limited
7.12.1 Company profile
7.12.2 Representative Antibody Drug Conjugate Product
7.12.3 Antibody Drug Conjugate Sales, Revenue, Price and Gross Margin of Takeda Pharmaceutical Company Limited
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF ANTIBODY DRUG CONJUGATE
8.1 Industry Chain of Antibody Drug Conjugate
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF ANTIBODY DRUG CONJUGATE
9.1 Cost Structure Analysis of Antibody Drug Conjugate
9.2 Raw Materials Cost Analysis of Antibody Drug Conjugate
9.3 Labor Cost Analysis of Antibody Drug Conjugate
9.4 Manufacturing Expenses Analysis of Antibody Drug Conjugate
CHAPTER 10 MARKETING STATUS ANALYSIS OF ANTIBODY DRUG CONJUGATE
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
